Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Bladder Urothelial Carcinoma”

138 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 138 results

Early research (Phase 1)Study completedNCT01522820
What this trial is testing

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Who this might be right for
Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+62 more
Roswell Park Cancer Institute 18
Testing effectiveness (Phase 2)Study completedNCT03914794
What this trial is testing

Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Who this might be right for
Bladder CancerNMIBCNon-Muscle Invasive Bladder Cancer+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 30
Testing effectiveness (Phase 2)Study completedNCT01090466
What this trial is testing

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Cardiff University 15
Large-scale testing (Phase 3)Study completedNCT00445601
What this trial is testing

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Who this might be right for
Bladder Cancer
SWOG Cancer Research Network 406
Not applicableStudy completedNCT02700464
What this trial is testing

The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma

Who this might be right for
Bladder Cancer
Nucleix Ltd. 680
Testing effectiveness (Phase 2)Study completedNCT00002914
What this trial is testing

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Eastern Cooperative Oncology Group 40
Testing effectiveness (Phase 2)WithdrawnNCT02718742
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Who this might be right for
Recurrent Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma
Mayo Clinic
Very early researchStudy completedNCT00734994
What this trial is testing

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Who this might be right for
Transitional Cell Carcinoma of BladderSuperficial Bladder Cancer
Mark Dewhirst 15
Testing effectiveness (Phase 2)UnknownNCT03030157
What this trial is testing

Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma

Who this might be right for
Intravesical Instillation
RenJi Hospital 220
Large-scale testing (Phase 3)Study completedNCT00729287
What this trial is testing

Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
KU Leuven 276
Testing effectiveness (Phase 2)Study completedNCT00047216
What this trial is testing

Tipifarnib in Treating Patients With Recurrent Bladder Cancer

Who this might be right for
Bladder Cancer
University Health Network, Toronto
Testing effectiveness (Phase 2)Study completedNCT00006376
What this trial is testing

R115777 in Treating Patients With Advanced Bladder Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
H. Lee Moffitt Cancer Center and Research Institute
Not applicableUnknownNCT06564363
What this trial is testing

The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Wuhan Ammunition Life-tech Co., Ltd 148
Testing effectiveness (Phase 2)Study completedNCT00055835
What this trial is testing

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Who this might be right for
Bladder CancerUrethral Cancer
SWOG Cancer Research Network 7
Early research (Phase 1)Study completedNCT00016237
What this trial is testing

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Who this might be right for
Bladder CancerKidney CancerLung Cancer
EMD Serono
Not applicableStudy completedNCT01007058
What this trial is testing

Markers of Response to Intravesical Bladder Cancer Therapy

Who this might be right for
Bladder Cancer
M.D. Anderson Cancer Center 150
Large-scale testing (Phase 3)Active Not RecruitingNCT05243550
What this trial is testing

Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 240
Large-scale testing (Phase 3)Ended earlyNCT00352079
What this trial is testing

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Who this might be right for
Bladder Cancer
NCIC Clinical Trials Group 41
Testing effectiveness (Phase 2)Study completedNCT00397488
What this trial is testing

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Memorial Sloan Kettering Cancer Center 78
Testing effectiveness (Phase 2)Looking for participantsNCT06770582
What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Who this might be right for
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8
National Cancer Institute (NCI) 160
Load More Results